Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial agreement with Genentech to evaluate the safety tolerability and preliminary efficacy of Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor INCB24360 in combination with Genentech’s PD-L1
combination与发音含义,同义词,反义词,翻译,刑和更多的